(Q40412742)

20 September 2017

title

A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma (English)

1 reference

multicenter clinical trial

20 September 2017

main subject

0 references

0 references

1 reference

1

1 reference

20 September 2017

12

Antonio Palumbo

1 reference

20 September 2017

author name string

Maria Teresa Petrucci

2

1 reference

20 September 2017

Sara Bringhen

3

1 reference

20 September 2017

Tommasina Guglielmelli

4

1 reference

20 September 2017

Tommaso Caravita

5

1 reference

20 September 2017

Velia Bongarzoni

6

1 reference

20 September 2017

Alessandro Andriani

7

1 reference

20 September 2017

Giovanni D'Arena

8

1 reference

20 September 2017

Enrico Balleari

9

1 reference

20 September 2017

Giuseppe Pietrantuono

10

1 reference

20 September 2017

Mario Boccadoro

11

1 reference

20 September 2017

GIMEMA (Italian Group for Adult Hematologic Diseases)/Multiple Myeloma Working Party and the Italian Myeloma Network

13

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 October 2008

1 reference

20 September 2017

1 reference

20 September 2017

volume

113

1 reference

20 September 2017

issue

7

1 reference

20 September 2017

page(s)

1588-1595

1 reference

Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I--a randomized study. Myeloma Group of Western Sweden

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

Thalidomide as initial therapy for early-stage myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

The antineoplastic role of bisphosphonates: from basic research to clinical evidence.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

New developments of aminobisphosphonates: the double face of Janus.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

Anti-myeloma activity of pamidronate in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

Pamidronate for early-stage, untreated myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

Zoledronic acid: past, present and future roles in cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

International staging system for multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

Role of ozone therapy in the treatment of osteonecrosis of the jaws in multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

Osteonecrosis of the jaw related to the use of bisphosphonates.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23783

7 January 2021

Identifiers

DOI

10.1002/CNCR.23783

1 reference

20 September 2017

1 reference